Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. - Wikidata - wikimedia - TriplyDB

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

http://www.wikidata.org/entity/Q34659415

about

Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment Kirsten Ras* oncogene: Significance of its discovery in human cancer research Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy Automated NMR fragment based screening identified a novel interface blocker to the LARG/RhoA complex Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery Deregulated expression of cytoskeleton related genes in the spinal cord and sciatic nerve of presymptomatic SOD1(G93A) Amyotrophic Lateral Sclerosis mouse model.Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma Direct Ras Inhibitors Identified from a Structurally Rigidified Bicyclic Peptide Library.Small-molecule modulation of Ras signaling.Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer.New Frontiers in Druggability Inhibitors of Ras-SOS Interactions.Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.Therapeutic Approaches to RAS Mutation.Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer KRAS - An Evolving Cancer Target Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells.SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers.KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies.A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma.Current status of the development of Ras inhibitors.K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?Synthesis, DNA binding affinity and anticancer activity of novel 4H-benzo[g][1,2,3]triazolo[5,1-c][1,4]oxazocines.5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis.Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.Targeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage?Neuropilin-1 (NRP-1)/GIPC1 pathway mediates glioma progression.Sequence-specific DNA alkylation targeting for Kras codon 13 mutation by pyrrole-imidazole polyamide seco-CBI conjugates.Insight into the Complexity of the i-Motif and G-Quadruplex DNA Structures Formed in the KRAS Promoter and Subsequent Drug-Induced Gene Repression.Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling.Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V).Selective Targeting of the KRAS Codon 12 Mutation Sequence by Pyrrole-Imidazole Polyamide seco-CBI Conjugates.Exploring the structural origins of cryptic sites on proteins.Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma

P2860

Q26740619-FC74F415-1E82-4CFD-844A-2863166129C4 Q26751212-B1AAEDD5-41BF-46FC-A778-195266E6A1E7 Q26828959-02AD8207-6DEA-484E-BCBE-702BB2BAE67A Q27027458-3B0C1C88-B14F-4EF7-86B1-64AB860A1F05 Q28078129-E350E5C4-2A8D-4F97-A05B-C41DE88ED4E1 Q28539542-4F7E2996-51C1-424C-B17A-9EB22F892FC6 Q28833740-844DD01C-A4AC-4F5C-B632-037B9124E0BD Q30390894-DC0ED836-11AE-463A-9A17-96C233C49D14 Q33659976-9ECEC9DD-21BB-4D6F-97FC-ECF6009411AB Q34246014-D1A7B3D8-8D88-4931-9552-8A7480C0A70B Q34271187-FCD7ECAC-FE0D-44DD-ABC0-1BDF7A6BB7FF Q35188280-524F51C8-D79B-4261-B8CB-418643D87A33 Q35207897-253B569E-03A2-4241-9521-68159ABD6DC2 Q35213124-1ECD270D-5025-4133-B12C-F476B1C8B20F Q35730955-9265B404-7B4C-4422-B8A6-7EFC6E102854 Q35859222-E52DCB70-C03B-4E51-ABB3-B95FF5F4FF9B Q36054290-0EAE021A-4F2A-413B-B45B-4F5C7407C2EB Q37122874-8C243ACD-FF6C-48D1-8371-76E05678300E Q37246286-977B02AD-887B-44E3-9C28-534728DDA6B5 Q37261936-6B18E14B-434C-4364-9EAC-0B33E3913867 Q37288375-4858C289-DF83-433C-AEB7-B1B2B01D1CF2 Q37698902-9AAF93CD-479E-4480-9843-AB611C8C9BCE Q37709450-30933F17-20E7-4159-8667-AE098B3B3B79 Q37743526-B5A86647-0AB4-4884-B949-173137CB5BE5 Q38534932-3A7DC9C1-E803-4F73-8976-EE5EF89CFDA0 Q38731776-745C2F9B-9407-4C45-8D43-F700D0792D7A Q38742130-67CE2337-FAD3-44BC-8A85-25105901BB91 Q38858308-F06A4463-5BFB-40EC-B47F-A15F537181F1 Q38891257-86537403-E1AC-4C62-A2F5-20B8376255E8 Q39367990-10A05DB2-E5C5-4DAC-BEA7-B322AB69847A Q42048668-719472D2-CBA0-4EEC-91DC-7FEC2E6D9C4F Q44303195-A313BE9B-8218-4F37-BBFD-5704707DBAD3 Q46357957-BC9192A9-7F64-4827-8AD4-2133EA06830A Q48031809-6F230DF3-AB96-471C-BFD8-E6A7886C8036 Q48198158-36A665BC-978B-48D7-A3D2-860D4329E1F6 Q48225794-2E22DD01-5445-4D24-B67F-94E9F73FBC0F Q53676358-7CBC0F82-8060-4237-878C-9840C1382632 Q53834774-BDCFE063-93D5-45A6-BAE2-BF7F47F99886 Q58552976-8A3822BE-811B-4237-9C44-59275CB11ECC Q58713519-9DBDCDC5-FBD9-4C1C-B6C1-01D9A6936B62

P2860

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

http://www.wikidata.org/entity/Q34659415

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Targeting mutant KRAS for anti ...... vel small molecule modulators.

@ast

Targeting mutant KRAS for anti ...... vel small molecule modulators.

@en

Targeting mutant KRAS for anti ...... vel small molecule modulators.

@nl

type

label

Targeting mutant KRAS for anti ...... vel small molecule modulators.

@ast

Targeting mutant KRAS for anti ...... vel small molecule modulators.

@en

Targeting mutant KRAS for anti ...... vel small molecule modulators.

@nl

prefLabel

Targeting mutant KRAS for anti ...... vel small molecule modulators.

@ast

Targeting mutant KRAS for anti ...... vel small molecule modulators.

@en

Targeting mutant KRAS for anti ...... vel small molecule modulators.

@nl

P1433

Q34659415-ED309102-BA62-4F99-AB12-5F250832C00C

P1476

Q34659415-FD1EE64A-4D36-4919-9896-68DE01AA923D

P2093

Q34659415-519F2C5B-3FA8-49CF-8782-DC93F5BC898C

Q34659415-68BA6CB5-219D-4BC6-9000-2CE3A42F6A9F

Q34659415-6F9D5211-62AA-47E5-A374-301677B7CA69

Q34659415-D5A591C9-9507-46FA-998C-5348819F5822

P2860

Q34659415-017DA134-A8B8-445A-A2E8-8BFB0A824470

Q34659415-02AFFDC8-D076-4998-9B0A-E7E168D9CF35

Q34659415-06D6042A-B97E-49C4-B6B6-3262F4F44731

Q34659415-08FFDD08-64AF-4097-83AC-746ACBB645AE

Q34659415-0B8DD33E-F5DB-4E56-B035-4E7FB5C6BBC4

Q34659415-0DA4B6B2-EE70-45EE-8A1B-9237439C2B05

Q34659415-0E03940D-88F3-4691-B03C-0918632BD687

Q34659415-0E9E9A14-38FD-4C5C-89C8-DDBF1AAC37EE

Q34659415-12D603F6-6648-4EE9-B7F6-9CE3C05C241B

Q34659415-161F34DF-6BF9-4876-9469-E3B1BC729CDD

P304

Q34659415-C1136AF8-DF33-4AB6-AA72-1C72ADD9A80B

P31

Q34659415-F6F1CC28-CE79-4872-AFE4-0BDB59F44F6B

P356

Q34659415-447F6B8F-406B-44F2-A867-4FE1A444FDB4

P407

Q34659415-7A2A82F7-9E97-4F32-A879-307FDE914940

P433

Q34659415-8AAD944E-D196-4A2E-B37B-3CE9D022E908

P478

Q34659415-E166C909-93A6-44C1-9365-5533340004BB

P577

Q34659415-B67333F9-BEEC-4F6B-AF94-656DBD4FB40B

P5875

Q34659415-18EFEC72-CB8A-4A92-8964-F2F8E3885C12

P698

Q34659415-529BF281-4369-4530-8364-A8AAE0E7C5E4

P932

Q34659415-27BE33DF-02E4-4663-B180-474AB4D6678A

P356

P1433

Journal of Medicinal Chemistry

P1476

Targeting mutant KRAS for anti ...... vel small molecule modulators.

@en

P2093

Brendan Frett

http://www.w3.org/2001/XMLSchema#string

Christine E Kaiser

http://www.w3.org/2001/XMLSchema#string

Hong-Yu Li

http://www.w3.org/2001/XMLSchema#string

Yuanxiang Wang

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Cloning and characterization of a mammalian prenyl protein-specific protease

Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator

Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum

Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases

Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

P304

5219-5230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM3017706

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236137870

http://www.w3.org/2001/XMLSchema#string

P698

23566315

http://www.w3.org/2001/XMLSchema#string

P932

4666308

http://www.w3.org/2001/XMLSchema#string